| 纯度 | >90%SDS-PAGE. |
| 种属 | Human |
| 靶点 | GP2b |
| Uniprot No | P0C6Y6 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 2-70aa |
| 氨基酸序列 | GSLWSKISQLFVDAFTEFLVSVVDIAIFLAILFGFTVAGWLLVFLLRVVCSALLRSRSAIHSPELSKVL |
| 预测分子量 | 13.7 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于GP2b(血小板糖蛋白IIb)重组蛋白的3篇参考文献示例，基于现有研究领域概括：
---
1. **标题**：*Expression of Human Platelet Glycoprotein IIb in Heterologous Cells: Evidence for Membrane Glycoprotein IIb–IIIa Complex Formation*
**作者**：Poncz M, et al.
**摘要**：该研究在CHO细胞中成功表达重组人GPIIb蛋白，证明其与GPIIIa自然结合形成功能性复合物，证实了该复合物在纤维蛋白原结合及血小板聚集中的关键作用。
2. **标题**：*Structural Basis of Integrin Regulation and Signaling*
**作者**：Xiao T, et al.
**摘要**：通过冷冻电镜解析重组GPIIb/IIIa复合物的结构，揭示了整合素在静息与活化状态的构象变化，为靶向该复合物的抗血栓药物设计提供结构依据。
3. **标题**：*Recombinant GPIIb/IIIa Fragment for Detection of HIT Antibodies*
**作者**：Suvarna S, et al.
**摘要**：开发基于重组GPIIb/IIIa蛋白片段的检测方法，用于肝素诱导血小板减少症(HIT)的快速诊断，显著提高抗体检测的特异性。
---
**说明**：以上文献为领域相关示例，实际引用时需核实具体来源及准确性。GPIIb通常与GPIIIa共表达形成复合物，单独重组GPIIb的研究相对较少，多数研究聚焦于GPIIb/IIIa复合物的功能与应用。
**Background of GPIIb Recombinant Protein**
Glycoprotein IIb (GPIIb), encoded by the *ITGA2B* gene, is a critical subunit of the heterodimeric integrin receptor αIIbβ3 (GPIIb/IIIa), predominantly expressed on platelets. This receptor plays a central role in hemostasis and thrombosis by mediating platelet aggregation. Upon platelet activation, GPIIb/IIIa undergoes conformational changes, enabling binding to fibrinogen and von Willebrand factor (vWF), which crosslinks adjacent platelets to form clots. Dysregulation of this process is implicated in cardiovascular diseases, making GPIIb/IIIa a key therapeutic target.
Recombinant GPIIb protein is engineered using biotechnological platforms (e.g., mammalian or insect cell systems) to produce the extracellular domain or full-length protein for research and therapeutic applications. Its production allows detailed study of integrin activation mechanisms, ligand-binding specificity, and signaling pathways. Additionally, recombinant GPIIb facilitates the development of antiplatelet drugs, such as GPIIb/IIIa inhibitors (e.g., abciximab), used to prevent thrombotic events in high-risk patients.
Beyond drug discovery, recombinant GPIIb serves as a vital tool in diagnostic assays for platelet disorders, including Glanzmann thrombasthenia, a genetic deficiency of GPIIb/IIIa. It also aids in generating antibodies for research or clinical diagnostics. Furthermore, structural studies using recombinant GPIIb have revealed insights into integrin dynamics, informing the design of targeted therapies with improved efficacy and safety.
Overall, recombinant GPIIb protein bridges fundamental research and clinical innovation, advancing our understanding of platelet biology and enabling therapeutic strategies for thrombotic and bleeding disorders.
×
